How should I manage a 43-year-old male on amlodipine and atenolol who presents with uncontrolled hypertension, low-grade fever, elevated high-sensitivity C-reactive protein, borderline hypertriglyceridemia, low vitamin B12, and vitamin D deficiency?

Management of Uncontrolled Hypertension with Systemic Inflammation

This patient requires immediate optimization of his antihypertensive regimen by adding a thiazide-like diuretic (chlorthalidone or indapamide) to his current amlodipine and atenolol, while simultaneously investigating the source of his fever and elevated inflammatory markers.

Immediate Hypertension Management

Current Regimen Assessment

The patient's BP remains 160/100 mmHg despite amlodipine 5 mg and atenolol 50 mg for one month—this represents uncontrolled hypertension requiring escalation. His current regimen is suboptimal because:

• Beta-blocker (atenolol) is not first-line therapy unless there are compelling indications like angina, post-MI, or heart failure 1
• The combination lacks a RAS blocker (ACE inhibitor or ARB), which is the preferred foundation for dual therapy 1

Recommended Antihypertensive Strategy

Add a thiazide-like diuretic immediately (chlorthalidone 12.5-25 mg or indapamide 1.25-2.5 mg daily) to achieve three-drug therapy 1. The 2024 ESC guidelines explicitly recommend escalating to three-drug combination therapy when BP is not controlled with two drugs 1.

Consider transitioning the regimen once BP is controlled:

• Optimal three-drug combination: ACE inhibitor or ARB + amlodipine + thiazide-like diuretic (preferably as single-pill combination) 1
• Evidence shows adding a diuretic is more effective than increasing amlodipine dose in patients uncontrolled on dual therapy 2
• Beta-blockers should be reserved for specific indications (angina, post-MI, heart failure, rate control) 1

Target BP: 120-129/70-80 mmHg to reduce cardiovascular morbidity and mortality 1

Fever and Inflammatory Workup

Elevated hs-CRP (12.43 mg/L) Requires Investigation

The markedly elevated hs-CRP (>10 mg/L) suggests active inflammation or infection, not just cardiovascular risk. This level far exceeds the cardiovascular risk threshold of 2 mg/L 3.

Immediate diagnostic steps:

• Complete blood count with differential (already shows borderline thrombocytopenia at 134)
• Blood cultures if fever persists
• Chest X-ray to exclude pneumonia
• Urinalysis and urine culture
• Erythrocyte sedimentation rate (ESR)
• Consider infectious disease workup: tuberculosis screening, HIV testing, hepatitis panel depending on risk factors
• Autoimmune screening if infectious workup negative: ANA, RF, anti-CCP
• Echocardiogram to exclude endocarditis given persistent fever

Critical Pitfall

Do not attribute the elevated hs-CRP solely to cardiovascular risk—levels >10 mg/L typically indicate acute inflammation, infection, or autoimmune disease requiring specific treatment 3.

Metabolic Abnormalities

Hypertriglyceridemia (211 mg/dL)

• Lifestyle modifications: reduce refined carbohydrates, increase omega-3 fatty acids, weight loss if overweight
• Consider fibrate therapy (fenofibrate) if lifestyle modifications fail after 3 months
• Triglycerides >200 mg/dL increase cardiovascular risk

Vitamin B12 Deficiency (172 pg/mL, normal >200)

• Start vitamin B12 supplementation: 1000 mcg daily orally or 1000 mcg IM weekly for 4-8 weeks, then monthly
• Check methylmalonic acid and homocysteine if diagnosis uncertain
• Evaluate for pernicious anemia (anti-intrinsic factor antibodies) or malabsorption

Vitamin D Deficiency (15.6 ng/mL, target >30)

• Start vitamin D3 supplementation: 2000-4000 IU daily
• Recheck level in 3 months

Laboratory Abnormalities Requiring Attention

MCHC 50.8 g/dL (Critical Value)

This is impossibly high (normal 32-36 g/dL) and represents either:

• Laboratory error—repeat immediately
• Hemolysis in sample
• Severe spherocytosis (unlikely without anemia)

Action: Repeat CBC immediately with peripheral blood smear examination.

Borderline Thrombocytopenia (134 × 10³/µL)

Combined with fever and elevated CRP, consider:

• Viral infection
• Early sepsis
• Medication effect (atenolol rarely causes thrombocytopenia)
• Autoimmune disorder
• Monitor platelet count weekly until stable

Secondary Hypertension Screening

Given young age (43 years) and resistant hypertension, screen for secondary causes 4, 1:

Essential screening tests:

• Aldosterone-to-renin ratio (primary aldosteronism—most common secondary cause)
• 24-hour urine metanephrines or plasma metanephrines (pheochromocytoma)
• Renal artery duplex ultrasound or CT angiography (renovascular hypertension)
• Sleep study if symptoms of obstructive sleep apnea (snoring, daytime somnolence)
• TSH (thyroid dysfunction)

Review all medications for BP-interfering agents: NSAIDs, decongestants, oral contraceptives, corticosteroids, stimulants 4.

Follow-up Timeline

• 1 week: Repeat CBC with smear, review infectious workup results
• 2-4 weeks: Assess BP response to added diuretic, fever resolution
• 3 months: Target BP control achieved, reassess need for regimen optimization, recheck vitamin levels
• Ongoing: Monitor for resolution of inflammatory markers once underlying cause treated

Key Clinical Pitfalls to Avoid

1. Do not ignore the fever—this is not a hypertensive urgency; the elevated hs-CRP demands infectious/inflammatory investigation
2. Do not continue suboptimal antihypertensive regimen—beta-blocker without compelling indication is not guideline-concordant
3. Do not miss secondary hypertension—young age and treatment resistance warrant screening
4. Do not overlook the MCHC value—this critical abnormality requires immediate repeat testing
5. Do not delay vitamin supplementation—both B12 and D deficiencies contribute to cardiovascular risk and require correction